诺和诺德“大换血”，7名高管集体出走

Core Insights - Novo Nordisk is undergoing significant leadership changes, with seven executives, including Chairman Helge Lund, set to leave after the extraordinary general meeting on November 14 [1][2] - The departure is attributed to disagreements between the Novo Nordisk Board and its controlling shareholder, the Novo Nordisk Foundation, regarding the future composition of the board [1][3] - The foundation has proposed new board members, including Lars Rebien Sørensen as the new chairman, aiming to support the company's transformation and growth strategies [2][3] Leadership Changes - Seven executives, including Helge Lund and Vice Chairman Henrik Poulsen, will not participate in the upcoming election [2] - Kasim Kutay and several employee-elected board members will remain in their positions [2] - Sørensen's core objectives as chairman will include supporting the new management's transformation plan and identifying a successor to lead the company into the 2030s [3] Recent Appointments - Maziar Mike Doustdar has been appointed as the new CEO, succeeding Lars Fruergaard Jørgensen [4] - Doustdar has a strong background in international operations and is tasked with three strategic priorities: enhancing innovation, fostering a high-performance culture, and optimizing cost structures [5] Organizational Restructuring - Novo Nordisk announced a significant restructuring plan, including a global workforce reduction of approximately 9,000 employees to streamline operations and improve decision-making speed [5] - The restructuring is seen as necessary to adapt to the rapidly changing market, particularly in the obesity treatment sector [5] Market Competition - Novo Nordisk faces intensified competition in the GLP-1 market, particularly from Eli Lilly, which is rapidly gaining ground [7][9] - Recent announcements regarding price reductions for diabetes medications have led to stock price declines for both companies [7] - Novo Nordisk's sales figures for semaglutide reached 112.76 billion Danish kroner (approximately $16.63 billion) in the first half of the year, surpassing Eli Lilly's sales of its competing products [9][10] Financial Performance - Novo Nordisk has lowered its revenue and operating profit forecasts for 2025, reflecting slower market expansion and increased competition [10] - The company expects revenue growth of 8% to 14% and operating profit growth of 10% to 16%, down from earlier projections [10] - Despite these challenges, Novo Nordisk continues to invest in expanding the market presence of its weight loss and diabetes medications [11]